Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats

Authors

  • Nazila Jamshidi,

    Corresponding author
    1. Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy (Monash University), 381 Royal Parade, Parkville 3052, Victoria, Australia
    Search for more papers by this author
  • David A Taylor

    1. Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy (Monash University), 381 Royal Parade, Parkville 3052, Victoria, Australia
    Search for more papers by this author

Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy (Monash University), 381 Royal Parade, Parkville 3052, Victoria, Australia. E-mail: nazila.jamshidi@vcp.monash.edu.au

Abstract

This investigation reports the possible role of the endocannabinoid anandamide in modulating appetitive behaviour. Given that cannabinoids have been used clinically to stimulate appetite in HIV and cancer chemotherapy patients, there has been a renewed interest in the involvement of cannabinoids in appetite modulation. This is the first report on the administration of anandamide into the ventromedial hypothalamus. Pre-satiated rats received an intrahypothalamic injection of anandamide (50 ng 0.5 μl−1) followed by measurement of food intake at 3 h post injection. Administration of anandamide induced significant hyperphagia. Pretreatment with the selective CB1 cannabinoid antagonist SR 141716 (30 μg 0.5 μl−1), 30 min prior to anandamide injection resulted in an attenuation of the anandamide-induced hyperphagia (P<0.001). This study demonstrates that intrahypothalamic anandamide initiates appetite by stimulation of CB1 receptors, thus providing evidence on the involvement of hypothalamic endocannabinoids in appetite initiation.

British Journal of Pharmacology (2001) 134, 1151–1154; doi:10.1038/sj.bjp.0704379

Ancillary